Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.65 |
| ▸ | DRD3 | P35462 | 5/20 | 0.65 |
| ▸ | DRD1 | P21728 | 2/20 | 0.65 |
| ▸ | DRD4 | P21917 | 1/20 | 0.65 |
| ▸ | DRD5 | P21918 | 1/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 12/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43344 | 0.79 | DRD2 (0.66) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL7075328 | 0.79 | AOC3 (0.59) | DRD2DRD3DRD1OPRK1OPRM1 | |
| SCHEMBL11653919 | 0.79 | DRD2 (1.00) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL22100445 | 0.78 | DRD2 (0.59) | DRD2DRD3DRD1DRD4DRD5 | |
| Hydrochloric Acid SCHEMBL4067518 | 0.78 | DRD2 (0.64) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL18114808 | 0.77 | OPRK1 (0.61) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL216654 | 0.77 | DRD2 (0.67) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL29473925 | 0.77 | DRD2 (0.67) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL18122716 | 0.76 | OPRK1 (0.91) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL723832 | 0.76 | DRD2 (0.74) | DRD2DRD3DRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197799-A1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-08-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197799-A1 | HYDROXYLAMINE DERIVATIVES | C9, C1S, HTT | DRD2 392/4885DRD3 245/4885DRD1 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.